top of page

- Nov 2, 2022

Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel

Press Release - Phase 3 Trials

.pdf

Download PDF • 102KB

Recent Posts

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief

Neurotech Chief Medical Officer authors article in The Ophthalmologist

Neurotech Chief Medical Officer authors article in The Ophthalmologist

bottom of page